In this Issue:
FOLFIRI plus cetuximab or bevacizumab in mCRC
FOLFOXIRI + bevacizumab in mCRC
Adjuvant FOLFOX for rectal cancer
Multimodal treatment for peritoneal metastases
Prognostic value of miR-21 expression
Diagnostic value of stool miR-221
RAS mutation characteristics
Proximal vs distal tumour characteristics
Poor survival in BRAF-mutated mCRC
Older patients tolerate anti-EGFR therapies
Please login below to download this issue (PDF)